Our 5 research axes
Servier focuses its R&D on 5 therapeutic areas. Within each of them,
the Group has chosen to specialize in a limited number of diseases
where medical needs remain major.
the Group has chosen to specialize in a limited number of diseases
where medical needs remain major.
Immune-inflammatory diseases
10%
Of cases are severe
and do not respond to any treatment
and do not respond to any treatment
30.000
Patients with systemic scleroderma in Europe
189.000
Patients with Sjögren's disease,
the 2nd most common autoimmune disease
the 2nd most common autoimmune disease
Immune-inflammatory diseases, or simply autoimmune diseases, refer to many conditions that are triggered or characterized by an inadequate immune-system response. Most of the time, these diseases have high frequency, severity and no curative treatments exist.
Our research aims to discover innovative medicines for 3 diseases that are very disabling for patients and have a major impact on public health: systemic lupus erythematosus, of which 10% are severe and do not respond to any treatment; Systemic scleroderma, which affects about 30,000 patients in Europe, and Sjögren’s disease, the second most frequent autoimmune disease after rheumatoid arthritis which affects approximately 189,000 patients in Europe.
These pathologies are the subject of intense fundamental clinical research and we have developed partnerships with academic teams and internationally renowned biotech companies to discover and develop new drugs capable of acting on the immune system. For example, research programs are underway in systemic lupus erythematosus with ILTOO Pharma and in Sjögren’s disease with OSE Immunotherapeutics.